<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01270308</url>
  </required_header>
  <id_info>
    <org_study_id>P-699/08</org_study_id>
    <nct_id>NCT01270308</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Lansoprazole DR Capsules 30 mg in Fasting Conditions</brief_title>
  <official_title>Open Label, Randomized, Two-treatment, Three-period, Three-sequence, Partial Replicate Oral Bioequivalence Study of Lansoprazole 30 mg DR Capsules of Dr.Reddy's Laboratories Limited, India Comparing With That of PREVACID® (Containing Lansoprazole) 30 mg DR Capsules of TAP Pharmaceuticals Inc. USA, in Healthy, Adult, Human Subjects Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to compare the relative bioavailability of Lansoprazole DR
      Capsules 30 mg with Prevacid® Capsules 30 mg under fasting conditions in healthy adult human
      subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      open label, randomized, two-treatment, three-period, three-sequence, partial replicate oral
      bioequivalence study of Lansoprazole 30 mg DR Capsules of Dr.Reddy's Laboratories Limited,
      India comparing with that of PREVACID® (containing Lansoprazole) 30 mg DR Capsules of TAP
      Pharmaceuticals Inc. USA, in healthy, adult, human subjects under fasting conditions. 48
      healthy, adult, human subjects were enrolled in the study and 42 subjects were completed the
      study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax and AUC parameters</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lansoprazole DR Capsules 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lansoprazole DR Capsules 30 mg of Dr.Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevacid 30 mg Capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prevacid 30 mg Capsules of TAP Pharmaceuticals Inc. USA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole</intervention_name>
    <description>Lansoprazole DR Capsules 30 mg</description>
    <arm_group_label>Lansoprazole DR Capsules 30 mg</arm_group_label>
    <arm_group_label>Prevacid 30 mg Capsules</arm_group_label>
    <other_name>Prevacid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        i. Provided written informed consent.

        ii. Subject who were healthy, adult, human beings within 18 and 45 years of age (both
        inclusive) weighing at least 50 kg.

        iii. Subject having a body mass index between 18.0 and 29.9 (both inclusive), calculated as
        weight in Kg/height in m2.

        iv. Subject having a normal health as determined by medical history, physical examination
        and laboratory investigation performed within 28 days prior to the commencement of the
        study. (Laboratory values must be within normal limits or considered by the physician
        /investigator to be of no clinical significance).

        v. Female Subjects of child bearing potential practicing an acceptable method of birth
        control for the duration of the study as judged by the investigator(s), such as condoms,
        foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.

          -  postmenopausal for at least 1 year.

          -  surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy
             has been performed on the subject)

        Exclusion Criteria:

        i. Subject who were incapable of understanding the informed consent.

        ii. Systolic blood pressure less than 90 mm of Hg or more than 140 mm of Hg.

        iii. Diastolic blood pressure less than 60 mm of Hg or more than 90 mm of Hg.

        iv. Oral temperature is below 95.0°F or above 98.6°F.

        v. Pulse rate below 50/min or above 100/min.

        vi. History of hypersensitivity or idiosyncratic reaction to investigational drug product
        or any other related drugs.

        vii. Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal
        function.

        viii. Consumption of grapefruit for the past ten days prior to the check-in, in each
        period.

        ix. Regular smoker who has a habit of smoking more than nine cigarettes per day and has
        difficulty in abstaining from smoking during sample collection period.

        x. Habit of alcoholism and difficulty in abstaining from alcohol during the sample
        collection period.

        xi. Difficulty in abstaining from xanthene containing food or beverages (like tea, coffee,
        chocolates and cola drinks) during the sample collection period.

        xii. Intake of over the counter (OTC) or prescribed medications and enzyme modifying
        medication or systemic medication for the last 30 days before dosing.

        xiii. Clinically significant abnormalities and / or with significant diseases.

        xiv. Confirmed positive in alcohol screening.

        xv. Confirmed positive in selected drug of abuse.

        xvi. Subjects who had participated in any other clinical investigation using experimental
        drug/donated blood in past 90 days before the date of start of study

        xvii. Confirmed positive in urine pregnancy test.

        xviii. Female detected to be pregnant, breast feeding or who is likely to become pregnant
        during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr.M.Venkat Jayanth, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bioserve Clinical Research (P) Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bioserve Clinical Research (P) Ltd</name>
      <address>
        <city>Balanagar</city>
        <state>Hyderabad</state>
        <zip>500 037</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2011</study_first_submitted>
  <study_first_submitted_qc>January 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2011</study_first_posted>
  <last_update_submitted>January 4, 2011</last_update_submitted>
  <last_update_submitted_qc>January 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Manager - Research &amp; Development</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>two way crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

